Description
This article continues the discussion of therapeutic drug monitoring begun in the first article in the series, and illustrates the application of the fundamental principles of monitoring to cardioactive drugs, antibiotics, lithium, bronchodilators, immunosuppressants and anti-neoplastic agents. New developments in drug monitoring (pharmacodynamic monitoring and the use of pharmacogenetics) are also discussed briefly.
